Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

Overview

Chronic Thromboembolic Pulmonary Hypertension (CTEPH) is a form of pulmonary hypertension that results from persistent, organized blood clots (thromboemboli) that obstruct the pulmonary arteries and cause elevated pressure in the lungs’ circulation. Over time, the blockage leads to remodeling of the vessel walls, right‑ventricular strain, and progressive shortness of breath. Unlike acute pulmonary embolism, the clots in CTEPH do not dissolve spontaneously and become fibrotic, requiring specific diagnostic and therapeutic approaches.^[1][2]

Symptoms Checklist

• Shortness of breath, especially during exertion
• Fatigue or reduced exercise tolerance
• Chest discomfort or tightness
• Swelling (edema) of the ankles, feet, or abdomen
• Light‑headedness or fainting (syncope)
• Persistent cough, sometimes with blood‑tinged sputum
• Palpitations or rapid heart rate
• Blue‑tinged lips or fingertips (cyanosis) in severe cases

Risk Factors

People with the following histories are at higher risk of developing CTEPH:

• Previous acute pulmonary embolism (PE) – especially if untreated or recurrent
• Blood clotting disorders (e.g., factor V Leiden, antiphospholipid syndrome)
• Chronic inflammatory conditions (e.g., inflammatory bowel disease, lupus)
• History of splenectomy or certain cardiac surgeries
• Malignancy or chemotherapy that predisposes to thrombosis
• Obesity, sedentary lifestyle, and smoking
• Age > 50 years (though CTEPH can occur at any age)

Diagnosis

Diagnosing CTEPH involves a stepwise approach to confirm both the presence of pulmonary hypertension and the chronic thromboembolic obstruction.

1. Clinical evaluation – detailed history, physical exam, and assessment of risk factors.
2. Baseline tests
   • Electrocardiogram (ECG) – may show right‑heart strain.
   • Chest X‑ray – can reveal enlarged pulmonary arteries or right‑ventricular enlargement.
3. Echocardiography – non‑invasive screening tool that estimates pulmonary artery pressure and evaluates right‑ventricular function.^[3]
4. Ventilation‑Perfusion (V/Q) Scan – the most sensitive screening test for detecting mismatched perfusion defects typical of CTEPH.
5. Computed Tomography Pulmonary Angiography (CTPA) or Magnetic Resonance Angiography (MRA) – provides detailed anatomic visualization of chronic thrombi.
6. Right Heart Catheterization – gold‑standard for confirming pulmonary hypertension (mean pulmonary artery pressure ≥ 25 mmHg) and measuring hemodynamics.
7. Pulmonary Angiography (digital subtraction) – performed in specialized centers to map surgical candidates for pulmonary endarterectomy.

Treatment Options

Therapy is individualized based on disease severity, clot location, and patient comorbidities.

1. Surgical Intervention

• Pulmonary Endarterectomy (PEA) – the definitive curative procedure for operable CTEPH. It removes organized thrombi from the main pulmonary arteries under deep hypothermic circulatory arrest. Success rates in experienced centers exceed 70% with marked hemodynamic improvement.^[4]

2. Interventional (Non‑Surgical) Therapies

• Balloon Pulmonary Angioplasty (BPA) – percutaneous dilation of distal obstructed vessels; useful for patients deemed inoperable or with residual disease after PEA.
• Medical Therapy – targeted pulmonary‑arterial hypertension drugs are used when surgery is not feasible or as bridge therapy:
  • Riociguat (a soluble guanylate cyclase stimulator) – FDA‑approved for CTEPH.^[5]
  • Endothelin receptor antagonists (e.g., bosentan, macitentan) – off‑label use in selected cases.
  • Phosphodiesterase‑5 inhibitors (e.g., sildenafil) – may improve exercise capacity.

3. Anticoagulation

Life‑long anticoagulation (warfarin, direct oral anticoagulants, or low‑molecular‑weight heparin) is essential to prevent new thromboembolic events.^[1]

4. Supportive & Home‑Based Measures

• Oxygen therapy for resting hypoxemia.
• Diuretics to manage right‑heart failure‑related edema.
• Supervised exercise and cardiac rehabilitation programs.
• Vaccinations (influenza, pneumococcal) to reduce respiratory infections.

Prevention

While CTEPH cannot always be prevented, risk reduction strategies focus on avoiding acute pulmonary embolism and minimizing clot propagation.

• Prompt treatment of acute PE with anticoagulation.
• Identify and manage inherited or acquired thrombophilias.
• Maintain a healthy weight, stay physically active, and avoid prolonged immobility (e.g., use compression stockings during long travel).
• Quit smoking and limit alcohol intake.
• Regular follow‑up after an acute PE to ensure clot resolution (repeat imaging if symptoms persist).

Living With Chronic Thromboembolic Pulmonary Hypertension

Effective self‑management can improve quality of life and functional capacity.

• Medication adherence – take anticoagulants and any pulmonary‑hypertension drugs exactly as prescribed.
• Monitor symptoms – keep a daily log of breathlessness, weight (for fluid retention), and exercise tolerance.
• Exercise safely – engage in low‑to‑moderate intensity activities (walking, stationary cycling) under the guidance of a pulmonary rehabilitation specialist.
• Nutrition – a heart‑healthy diet low in sodium helps control fluid overload.
• Regular follow‑up – at least every 3–6 months with a PH specialist; more frequent if on anticoagulation.
• Psychosocial support – consider counseling, support groups, or patient organizations (e.g., Pulmonary Hypertension Association).
• Travel considerations – carry a medical alert card, ensure access to anticoagulation monitoring, and plan for supplemental oxygen if needed.

When to Seek Emergency Care

Immediate medical attention is required if you experience any of the following:

• Sudden, severe shortness of breath or chest pain.
• Fainting or near‑fainting episodes.
• Rapid, irregular heartbeat (palpitations) accompanied by dizziness.
• Sudden swelling of the legs or abdomen with rapid weight gain.
• Blue discoloration of lips, fingertips, or skin (cyanosis).
• Signs of a bleeding complication from anticoagulation (e.g., unusual bruising, blood in urine or stool, prolonged nosebleeds).

Medical Disclaimer: This guide is for informational purposes only and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider for personalized care. The content reflects current knowledge as of the publication date and may not include the latest research or clinical guidelines.

References

1. Mayo Clinic. “Chronic thromboembolic pulmonary hypertension (CTEPH).” https://www.mayoclinic.org.
2. National Heart, Lung, and Blood Institute (NHLBI). “Pulmonary Hypertension.” https://www.nhlbi.nih.gov.
3. Cleveland Clinic. “Pulmonary Hypertension Overview.” https://my.clevelandclinic.org.
4. Johns Hopkins Medicine. “Pulmonary Endarterectomy for CTEPH.” https://www.hopkinsmedicine.org.
5. U.S. Food & Drug Administration. “Riociguat (Adempas) Prescribing Information.” https://www.fda.gov.